Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Total Valuation
Cardiff Oncology has a market cap or net worth of $173.63M. The enterprise value is $149.53M.
Market Cap$173.63M
Enterprise Value$149.53M
Share Statistics
Cardiff Oncology has 66.52M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66.52M
Owened by Insiders3.57%
Owened by Instutions22.23%
Financial Efficiency
Cardiff Oncology’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -57.59%.
Return on Equity (ROE)-54.77%
Return on Assets (ROA)-46.74%
Return on Invested Capital (ROIC)-57.59%
Return on Capital Employed (ROCE)-58.08%
Revenue Per Employee$21,375
Profits Per Employee-$1,419,718.75
Employee Count32
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cardiff Oncology is -4.55. Cardiff Oncology’s PEG ratio is -2.12.
PE Ratio-4.55
PS Ratio302.78
PB Ratio2.49
Price to Fair Value2.49
Price to FCF-5.47
Price to Operating Cash Flow-5.49
PEG Ratio-2.12
Income Statement
In the last 12 months, Cardiff Oncology had revenue of $684.00K and earned -$45.43M in profits. Earnings per share was -$0.98.
Revenue$684.00K
Gross Profit$477.00K
Operating Income-$48.65M
Pretax Income-$45.44M
Net Income-$45.43M
EBITDA-48.25M
Earnings Per Share (EPS)-0.98
Cash Flow
In the last 12 months, operating cash flow was -$37.69M and capital expenditures -$80.00K, giving a free cash flow of -$37.77M billion.
Operating Cash Flow-$37.69M
Free Cash Flow-$37.77M
Free Cash Flow per Share-$0.57
Dividends & Yields
Cardiff Oncology pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-18.27%
Earnings Yield-21.97%
Stock Price Statistics
Beta1.34
52-Week Price Change-55.97%
50-Day Moving Average3.83
200-Day Moving Average3.10
Relative Strength Index (RSI)32.85
Average Volume (3m)1.34M
Important Dates
Cardiff Oncology upcoming earnings date is May 1, 2025, After Close.
Last Earnings DateFeb 27, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Cardiff Oncology as a current ratio of 7.08, with Debt / Equity ratio of 0.02
Current Ratio7.08
Quick Ratio7.08
Debt to Market Cap<0.01
Net Debt to EBITDA1.03
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cardiff Oncology has paid $58.72K in taxes.
Income Tax$58.72K
Effective Tax Rate0.00%
Enterprise Valuation
Cardiff Oncology EV to EBITDA ratio is -3.22, with an EV/FCF ratio of -4.15.
EV to Sales229.65
EV to EBITDA-3.22
EV to Free Cash Flow-4.15
EV to Operating Cash Flow-4.16
Balance Sheet
Cardiff Oncology has $91.75M in cash and marketable securities with $1.52M in debt, giving a net cash position of -$90.22M billion.
Cash & Marketable Securities$91.75M
Total Debt$1.52M
Net Cash-$90.22M
Net Cash Per Share-$1.36
Tangible Book Value Per Share$1.74
Margins
Gross margin is 100.00%, with operating margin of -7123.13%, and net profit margin of -6651.68%.
Gross Margin100.00%
Operating Margin-7123.13%
Pretax Margin-6655.20%
Net Profit Margin-6651.68%
EBITDA Margin-7123.13%
EBIT Margin-7123.13%
Analyst Forecast
The average price target for Cardiff Oncology is $15.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$15.25
Price Target Upside517.41%
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast40.16%
EPS Growth Forecast-2.76%